Q1 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
References
CosentyxⓇ
Matusiak Ł. Br J Dermatol. 2020;183(6):e171-e177.
1
2
G6 market estimations based on IQVIA PADDS 2021.
3 Kimball A, et al. N Engl J Med. 2016;375:422-434.
4
Data on file. IQVIA PADSS. Novartis Pharmaceuticals Corp; March 2023.
5 Kimball A, et al. Lancet. 2023;401(10378):747-761.
6
Post hoc analysis: patients with moderate to severe pain at baseline who improved to mild or no pain at Week 52.
7 Novartis data on file. SUNNY Clinical Study Program pooled data tables and post hoc analyses.
8 Between 1 in 100 and 1 in 1,000 exposed patients.
KesimptaⓇ
1 March 2023, IQVIA NPA (KesimptaⓇ) and IQVIA NPA adjusted by NSP (all others). B-cell therapies as portion of MS market in NBRx.
Refers to US unless otherwise stated.
2
3 Data on file.
4 The initial dosing period consists of 20 mg subcutaneous doses at Weeks 0, 1 and 2, thereafter once a month. Patient must take pen out of the refrigerator 15-30 minutes before self-administering.
5 Efficacy outcomes as measured by disability progression and brain volume change.
6
Cohen et al, Poster presented at American Academy of Neurology, Boston, 22-27 April 23.
7
Cohen et al, oral presentation at American Academy of Neurology, Boston, 22-27 April 23.
ZolgensmaⓇ
1 Based on US SMA incidence from NBS data & Zolgensma sales in eligible patients.
2 Wave 3 and 4 launch countries.
3 Mendell J. et al. Long-Term Follow-Up of Onasemnogene Abeparvovec Gene Therapy in Symptomatic Patients with Spinal Muscular Atrophy Type 1. Abstract presented at the 2023 MDA Clinical & Scientific Conference. March 19-22,2023.
4 Connolly A. et al. Intravenous and Intrathecal Onasemnogene Abeparvovec Gene Therapy in Symptomatic and Presymptomatic Spinal Muscular Atrophy: Long-Term Follow-Up Study. Abstract presented at the 2023 MDA Clinical &
Scientific Conference. March 19-22, 2023.
5 All but one achieved walking alone milestone before or without added therapy at the last data cut (May 2022).
94 Investor Relations | Q1 2023 Results
1 NOVARTIS | Reimagining MedicineView entire presentation